Introduction
Substituted oxazoles can be found in a wide variety of biologically active molecules of interest to the drug discovery community. Oxazole-containing biologically active natural products, 1 especially the diazonamide 1b and phorboxazole 1c families, exhibit anticancer properties, and a number of synthetic trisubstituted 2 and 2,5-disubstituted 3 oxazoles have been evaluated to show activity against diabetes, 2b gram-positive and gram-negative bacterial infections, 3a breast cancer, 3b and pancreatic cancer 3c (Figure 1 ). Moreover, substituted oxazoles can be utilized in agrochemicals, 4 fluorescent dyes, 5 polymers, 6 and also as ligands for transition-metal catalysis. 7 Consequently, the development of synthetic methods to access functionalized oxazoles is of great importance to synthetic organic chemists.
To date, various synthetic methods have been developed for the synthesis of substituted oxazoles. [8] [9] [10] In particular, a common strategy has been to convert an acyclic precursor to an oxazole ring. 8a-d,8i,9,10 A versatile cyclization strategy is the Robinson-Gabriel condensation, 8a-d which has been utilized to prepare a range of highly substituted and complex oxazoles (Scheme 1A). However, this method requires the use of Brönsted acid catalysts or Lewis acid reagents which limits the overall functional group tolerance of the transformation. Alternatively, enamides can serve as stable and easily accessible starting materials to afford oxazoles. 9, 10 Enamides bearing the β-vinylic C-heteroatom bonds (CBr, 9a-d C-I, 9e,f and C-S 9g ) have been isolated or generated in situ, which undergo facile intramolecular vinylation of the amide oxygen to provide a broader range of oxazoles under milder conditions (Scheme 1B). While this strategy is effective, a method for the cyclization of enamides to oxazoles, without the need for further vinylic C-H functionalization, would be a more direct and convenient means of obtaining the same products (Scheme 1C).
Our group previously reported the development of a sequential synthesis of 2,4,5-trisubstituted oxazoles via initial copper-catalyzed amidation of vinyl halides to form enamides, followed by intramolecular cyclization promoted by iodine (Scheme 2). 10 Unfortunately, the synthesis of mono-and disubstituted oxazoles still remained a limitation under the reported reaction conditions, and 2,5-disubstituted oxazoles were instead generated via a domino copper-catalyzed C-N/C-O coupling sequence starting from 1,2-dihaloalkenes and amides. Thus, the development of a direct cyclization of enamides to oxazoles without the need for a β-vinylic functional group remains an important challenge.
Recently, several examples of transition-metal-catalyzed methods for the direct vinylic C-H functionalization of enamides have been described. 11 Moreover, copper, as an inexpensive and readily available metal, has been widely utilized to facilitate C-O bond formation, via oxidative C-H functionalization, for the formation of various heterocycles. 12 We thus reasoned that a Cu-catalyzed direct oxidative cyclization of enamides to oxazoles via vinylic C-H functionalization might be plausible. In fact, during the preparation of this manuscript, Wendlandt and Stahl disclosed a similar method for the Cu-mediated oxidative cyclization of enamides to 2,5-disubstituted oxazoles (eq. 1). 13 Their method is attractive as it uses oxygen as the oxidant, albeit with a stoichiometric quantity of copper(II) chloride, to promote this cyclization. Herein, we report a method for the synthesis of a broad range of 2,5-disubstituted oxazoles via stepwise Cu-catalyzed amidation of vinyl halides to form enamides, followed by subsequent Cu-catalyzed oxidative cyclization, promoted by potassium persulfate, of the enamide intermediates under ambient conditions (Scheme 3).
(1)
Results and Discussion
We began our studies by subjecting (E)-N-styrylbenzamide (1a) to a catalytic amount of copper(II) bromide, using potassium persulfate as an oxidant (Table 1 , entry 1). Despite complete conversion of 1a, 2,5-diphenyloxazole (2a) was only obtained in 14% yield. 14 The use of tetrabutylammonium bromide (TBAB) as an additive, 15 which probably aids in the regeneration of CuBr 2 , led to a significant increase in yield (59%, Table 1, entry 2). Further, we found that the use of ethyl nicotinate (40 mol%) as a ligand for copper increased the yield up to 78% (Table 1, entry 3) . A number of electronically varied substituted pyridine ligands were evaluated (Table 1, entries 3-7) , and ethyl nicotinate was identified as the optimal ligand. In an attempt to reduce the loading of ethyl nicotinate, we found that by slightly increasing the amount of copper catalyst to 7.5 mol%, the amount of ethyl nicotinate could be lowered to 15 mol% while maintaining a high yield of product (Table 1, entry 9) . The use of CuBr 2 was also found to be much more effective than the other transition metal salts (CuCl 2 , FeBr 2 , and FeCl 2 ) ( Table 1, entries 11-13) . 16 In the absence of CuBr 2 , only a trace of 2a was obtained (Table 1, entry 14) .
With good reaction conditions, we set out to examine the substrate scope for the process ( Table 2) . The process tolerates a range of ortho-, meta-, and para-substituents on either or both aromatic rings of the enamide intermediate to generally afford 2,5-diaryloxazoles in good yields. Notably, chloro-and bromo-substituted diaryloxazoles (2d, 2l, and 2m) could be prepared, which render them as suitable substrates for further functionalization via a range of cross-coupling methods. Moreover, these conditions described also provide access to 2,5-diaryloxazoles bearing fluoro and trifluoromethyl substituents (2e, 2f, 2n, and 2o), which are often highly desirable in the synthesis of novel therapeutics. 17 Ortho-substitution on the enamide aryl groups was also well-tolerated, affording the corresponding oxazoles in high yields (2p, 2q). The presence of a highly electron-withdrawing nitro group on the benzamide region (2g, 2h) or of a strongly π-donating methoxy group on the β-styryl region (2i) 18 led to lower yields of the corresponding oxazoles.
Next, we sought to extend this methodology to include 2,5-disubstituted oxazoles bearing vinyl, alkyl, and heterocyclic substitution (Table 3) . Enamides bearing the styryl groups could be cyclized to afford the styryloxazoles (4a,b), including the natural product annuloline (4c). 19 Enamides bearing both cyclic and acyclic alkyl groups were also viable substrates (4d-f), although, interestingly, the cyclohexyl ring of oxazole 4f was partially oxidized to 1-cyclohexenyl (4f') during the course of the reaction. We were particularly pleased to discover that enamides bearing electron-rich 2-furyl, 2-and 3-thienyl, and Nbenzoyl-5-indolyl groups survived the oxidizing conditions to afford the corresponding oxazoles in moderate to high yields (4g-k). Unfortunately, an oxazole containing an Nmethyl-2-pyrrolyl group at the 2-position, as well as oxazoles bearing N-tosyl-2-pyrrolyl and 2-thienyl groups at the 5-position, could not be efficiently synthesized using the current conditions. Moreover, oxazoles with pyridyl groups, as well as an oxazole bearing an Nmethyl-2-imidazolyl group at the 2-position, could only be generated in low yields.
Regarding the mechanism of copper(II)-catalyzed oxidative cyclization of enamides to oxazoles, Wendlandt and Stahl have proposed that CuCl 2 acts as a single-electron oxidant, triggering the cyclization via a radical pathway (eq. 1). 13 We concur; in our case, CuBr 2 most likely serves as a single-electron oxidant, converting the electron-rich enamide 1a to an enamide radical cation (Scheme 4, transformation i), which then cyclizes to radical intermediate I (Scheme 4, transformation ii). 13 Subsequent oxidation of I by CuBr 2 provides the oxazole 2a (Scheme 4, transformation iii). The reduced form of copper, CuBr, is then oxidized by K 2 S 2 O 8 and reacts with TBAB to regenerate the CuBr 2 catalyst (Scheme 4, transformation iv).
Conclusion
In summary, we have developed an efficient room temperature catalytic oxidative cyclization of enamides to generate 2,5-disubstituted oxazoles by using catalytic amounts of CuBr 2 in conjunction with K 2 S 2 O 8 as an oxidant. This reaction protocol can tolerate enamide substrates bearing aryl, heteroaryl, vinyl, and/or alkyl substituents to afford the corresponding oxazoles in moderate to high yields. This transformation is complementary to the iodine-promoted cyclization of enamides to 2,4,5-trisubstituted oxazoles previously reported by our group.
Experimental Section General Information
Nuclear Magnetic Resonance spectra were recorded on a Bruker 400 MHz instrument at ambient temperature. All 1 H NMR spectra were measured in parts per million (ppm) relative to the signals for tetramethylsilane (TMS) added into the deuterated chloroform (CDCl 3 ) (0 ppm), or the signals for residual dimethyl sulfoxide (DMSO) in deuterated DMSO (DMSOd 6 ) (2.50 ppm). Data for 1 H NMR were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qu = quintet, m = multiplet, br = broad, ovrlp = overlap), coupling constants, and integration. All 13 C NMR spectra were reported in ppm relative to CDCl 3 (77.16 ppm) 20 or DMSO-d 6 (25.12 ppm) . 20 All 19 F NMR spectra were reported in ppm relative to a CFCl 3 external standard (0 ppm). Anhydrous acetonitrile (99.8%) was purchased from Alfa Aesar. Other commercial materials were used as received unless otherwise noted. Flash column chromatography was performed using Silicycle silica gel (ultra pure grade). (E)-(2-bromovinyl)benzene, 21 22 ((1E)-4-bromobuta-1,3-dien-1-yl)benzene 23 ((3Z) : (3E) = 2.6 : 1.0), and (E)-3-(3,4-dimethoxyphenyl)acrylamide 24 were prepared according to the literature procedures.
General Procedure for the Preparation of β-Aryl-vinyl Bromides
Adapted from a previously reported procedure with some modification. 21 A 250 mL roundbottom flask equipped with a Teflon-coated magnetic stir bar was charged with the cinnamic acid or its derivatives (1.0 equiv), N-bromosuccinimide (NBS) (1.05 equiv), and manganese(II) acetate tetrahydrate (Mn(OAc) 2 •4H 2 O) (20 mol%), followed by acetonitrile and water (1 : 1). The reaction mixture was stirred overnight at room temperature. The reaction mixture was then washed with excess water and ethyl acetate in a separation funnel. The aqueous fraction was further washed with ethyl acetate until most of the product has been extracted as judged by TLC analysis. The combined organic fraction was dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (ethyl acetate (EtOAc) : hexanes = 1 : 20) to afford the desired vinyl bromide. The ratio of (E) : (Z) isomers of vinyl bromide was determined by 1 H NMR spectroscopy.
(E)-4-(2-bromovinyl)phenyl acetate (S1) 25 ( ( 21%; pale-yellow oil. 1 H NMR of (E)-isomer (400 MHz, CDCl 3 ) δ 7.14-7.08 (ovrlp, 2H), 7.02-6.99 (ovrlp, 2H), 6.72 (d, J = 14.4 Hz, 1H) .
(E)-1-(2-bromovinyl)-2-methylbenzene (S5) 29
( (E) 
General Procedure for the Preparation of β-Heteroaryl-vinyl Bromides
Adapted from a previously reported procedure. 23 A 250 mL round-bottom flask was charged with a Teflon-coated magnetic stir bar, (bromomethyl)triphenylphosphonium bromide 30 (1.0 equiv), and potassium tert-butoxide (KO t Bu) (1.05 equiv). The reaction vessel was evacuated and backfilled with argon (this sequence was repeated a total of 3 times) and then cooled to -78 °C. Anhydrous THF (80 mL) was added slowly into the reaction mixture to give a yellow suspension which was stirred at -78 °C for 1 h. A solution of carboxaldehyde (0.9 equiv) in anhydrous THF (10 mL) was then introduced via syringe. The resulting reaction mixture was stirred at -78 °C for 1 h, after which time it was gradually warmed to room temperature and further stirred for 4 hours. The mixture was diluted with hexanes (100 mL) and filtered under vacuum. The filtrate was dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (ethyl acetate (EtOAc) / hexanes) to afford the desired vinyl bromide. The ratio of (Z) : (E) isomers was determined by 1 H NMR spectroscopy.
3-(2-Bromovinyl)thiophene (S6) 31
( (Z) (100 MHz, CDCl 3 ) 168. 6, 135.7, 134.4, 132.6, 132.1, 130.8, 130.7, 129.3, 128.7, 128.3, 126.3, 121.4, 116.2, 108.8, 105.7 . IR (neat cm -1 ) 1673, 1468, 1444, 1371, 1323, 1184, 1065, 882, 825, 793, 771, 737, 720, 696, 606 
Preparation of Enamides via Cu-Catalyzed Amidations of Vinyl Halides
Adapted from a previously reported procedure with some modification. 10 An oven-dried 25 mL re-sealable screw-cap test tube equipped with a Teflon-coated magnetic stir bar was charged with vinyl halide (if solid), amide, CuI, and K 2 CO 3 . The tube was then evacuated and backfilled with argon (this sequence was repeated a total of three times). Vinyl halide (if liquid) and N,N'-dimethylethylenediamine (DMEDA) were added into the tube followed by anhydrous THF via syringe. The sealed tube was placed in a pre-heated oil bath (80 °C). After stirring at the same temperature for 18 h, the reaction mixture was allowed to cool to room temperature. The reaction mixture was then extracted with ethyl acetate (EtOAc) (20 mL) and deionized water (100 mL) in a separation funnel. The aqueous fraction was further extracted with EtOAc (2 × 10 mL). The combined organic fractions were then dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography using the indicated solvent system as an eluent to afford the enamide substrates.
(E)-N-styrylbenzamide (1a) 33 Synthesized from (E)-(2-bromovinyl)benzene 21 6, 133.4, 131.9, 128.8, 128.5, 127.7, 126.3, 125.3, 124.2, 113 .0. IR (neat cm -1 ) 3302, 1637, 1522, 1483, 1310, 1288, 1171, 1074, 953, 927, 746, 691 .
(E)-4-methoxy-N-styrylbenzamide (1b)
Synthesized from (E)-(2-bromovinyl)benzene 21 ( 1.28 5, 162.2, 136.8, 129.6, 128.7, 126.1, 125.5, 125.2, 124.4, 113.7, 112.3, 55.4 . IR (neat cm -1 ) 3336, 1665, 1636, 1603, 1524, 1486, 1288, 1252, 1179, 1028, 949, 844, 749, 694, 668 34 Synthesized from (E)-(2-bromovinyl)benzene 21 9, 142.0, 136.7, 130.5, 129.1, 128.7, 127.7, 126.2, 125.2, 124.2, 112.6, 21.0 . IR (neat cm -1 ) 3219, 1624, 1523, 1485, 1309, 1285, 1185, 961, 835, 761, 737, 693, 636 . Hz, 2H), 7.70 (t, J = 7.6 Hz, 2H), 7.17 (t J = 7.2 Hz, 1H), 6.48 (d, J = 14.8 Hz, 1H 8, 136.5, 132.1, 129.6, 128.7, 128.6, 126.3, 125.3, 124.0, 113.3 . IR (neat cm -1 ) 3330, 1641, 1523, 1479, 1279, 1171, 1091, 1013, 941, 843, 747, 692, 670 3343, 1642, 1599, 1525, 1483, 1286, 1222, 1158, 942, 846, 747, 692, 655, 624, 604 8, 128.6, 126.5, 125.5 (q, 3 
(E)-4-methyl-N-styrylbenzamide (1c)

(E)-4-nitro-N-styrylbenzamide (1g)
Synthesized from (E)-(2-bromovinyl)benzene 21 4, 149.3, 138.9, 136.3, 129.1, 128.7, 126.6, 125.4, 123.8, 123.6, 114.2 . IR (neat cm -1 ) 3306, 1636, 1598, 1518, 1482, 1310, 1285, 1170, 1109, 937, 865, 852, 749, 685 35 Synthesized from (E)-(2-bromovinyl)benzene 21 (1.54 g, 8.4 mmol, 1.4 equiv), 3-nitrobenzamide (997 mg, 6.0 mmol, 1.0 equiv), K 2 CO 3 (1.66 g, 12.0 mmol, 2.0 equiv), CuI (572 mg, 3.0 mmol, 50 mol%), DMEDA (387 μL, 3.6 mmol, 60 mol%), and THF (12.0 mL, 0.5 M); EtOAc / hexanes = 1:5, then 1:2. 875 mg, 3.26 mmol, 54%; yellow solid. m. 9, 147.8, 136.3, 134.7, 134.1, 130.3, 128.8, 126.5, 126.4, 125.4 123.8, 122.3, 114 .0. IR (neat cm -1 ) 3301, 1638, 1524, 1348, 1177, 1074, 944, 909, 864, 818, 750, 714, 692, 666 .
(E)-3-nitro-N-styrylbenzamide (1h)
(E)-N-(4-methoxystyryl)benzamide (1i) 36
Synthesized from (E)-1-(2-bromovinyl)-4-methoxybenzene 21 (1.53 g, 7.2 mmol, 1.2 equiv), benzamide (727 mg, 6.0 mmol, 1.0 equiv), K 2 CO 3 (1.66 g, 12.0 mmol, 2.0 equiv), CuI (343 mg, 1.8 mmol, 30 mol%), DMEDA (387 μL, 3.6 mmol, 60 mol%), and THF (12.0 mL, 0. Hz, 1H), 3.74 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 163. 9, 158.0, 133.5, 131.8, 129.0, 128.5, 127.6, 126.5, 122.4, 114.2, 112.8, 55 .1. IR (neat cm -1 ) 3319, 1636, 1605, 1504, 1484, 1285, 1244, 1177, 1031, 942, 846, 811, 690, 664 .
(E)-4-(2-benzamidovinyl)phenyl acetate (1j)
Synthesized from (E)-4-(2-bromovinyl)phenyl acetate (S1) (1.86 g, 7.7 mmol, 1.1 equiv), benzamide (848 mg, 7.0 mmol, 1.0 equiv), K 2 CO 3 (1.26 g, 9.1 mmol, 1. 3, 164.1, 148.9, 134.3, 133.3, 132.0, 128.5, 127.7, 126.2, 124.3, 122.1, 112.1, 20.9 . IR (neat cm -1 ) 3304, 1755, 1639, 1505, 1371, 1331, 1226, 1016, 949, 915, 796, 694 . Anal. Calcd. for C 17 H 15 NO 3 : C, 72.58; H, 5.37. Found: C, 72.39; H, 5.27 . 13 Synthesized from (E)-1-(2-bromovinyl)-4-methylbenzene 21 5, 133.7, 133.4, 131.9, 129.4, 128.5, 127.6, 125.2, 123.4, 113.0, 20.8 . IR (neat cm -1 ) 3301, 1638, 1531, 1506, 1309, 1285, 1170, 956, 925, 794, 692 . Anal. Calcd. for C 16 H 15 NO: C, 80.98; H, 6.37. Found: C, 80.71; H, 6.41 .
(E)-N-(4-methylstyryl)benzamide (1k)
(E)-N-(4-chlorostyryl)benzamide (1l)
Synthesized from (E)-1-(2-bromovinyl)-4-chlorobenzene (1.31 g, 6.0 mmol, 1.0 equiv), benzamide (872 mg, 7.2 mmol, 1.2 equiv), K 2 CO 3 (1.66 g, 12.0 mmol, 2.0 equiv), CuI (286 mg, 1.5 mmol, 25 mol%), DMEDA (322 μL, 3.0 mmol, 50 mol%), and THF (12.0 mL, 0.5 M); EtOAc / hexanes = 1:7, then 1:3. 987 mg, 3.83 mmol, 64%; pale yellow solid. m. 135.7, 133.3, 132.0, 130.4, 128.6, 128.5, 127.7, 126.9, 125.0, 111.6 . IR (neat cm -1 ) 3338, 1634, 1516, 1479, 1326, 1298, 1275, 1166, 1091, 1010, 945, 852, 808, 716, 692, 657 135.9, 132.3, 131.5, 129.7, 127.3, 125.8, 124.9, 118.9, 112 .0. IR (neat cm -1 ) 3309, 1639, 1588, 1521, 1477, 1334, 1274, 1170, 1072, 1008, 946, 938, 839, 804, 753, 700, 679 
(E)-4-(tert-butyl)-N-(4-fluorostyryl)benzamide (1n)
Synthesized from ( 6, 34.7, 30.9. 19 F NMR (376 MHz, DMSO-d 6 ) δ: -115.9. IR (neat cm -1 ) 3243, 2968 , 1633 , 1532 , 1495 , 1319 , 1302 , 1283 , 1233 , 1171 , 1155 H, 6.78. Found: C, 76.55; H, 6.91 . N-(3,4-difluorostyryl) 3286, 1638, 1581, 1493, 1413, 1337, 1234, 1124, 995, 942, 868, 847, 814, 754, 708, 674 . Anal. Calcd. for C 18 H 17 F 2 NO 4 : C, 61.89; H, 4.91. Found: C, 61.91; H, 5.00. (E)-2-methyl-N-(2-methylstyryl)benzamide (1p) Synthesized from (E)-1-(2-bromovinyl)-2-methylbenzene (S5) (1.18 g, 6.0 mmol, 1.0 equiv), 2-methylbenzamide (973 mg, 7.2 mmol, 1.2 equiv), K 2 CO 3 (1.66 g, 12.0 mmol, 2.0 equiv), CuI (343 mg, 1.8 mmol, 30 mol%), DMEDA (397 μL, 3.6 mmol, 60 mol%), and THF (12.0 mL, 0.5 M); EtOAc / hexanes = 1:7; then 1:4. 890 mg, 3.54 mmol, 59%; white solid. m.p.: 184-185 °C. 1 H NMR (400 MHz, DMSO-d 6 ) δ: 10.57 (d, J = 10.0 Hz, 1H), 7.54-7.47 (ovrlp, 3H), 7.40 (t, J = 7.2 Hz, 1H), 7.31-7.28 (ovrlp, 2H), 7.18-7.15 (ovrlp, 2H), 7.09 (t, J = 7.2 Hz, 1H), 6.56 (d, J = 14.8 Hz, 1H), 2.41 (s, 3H), 2.27 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 166. 5, 135.9, 135.6, 135.1, 134.1, 130.7, 130.2, 130.0, 127.4, 126.2, 126.2, 125.6, 124.3, 124.0, 110.3, 19.5 . IR (neat cm -1 ) 3263, 1637, 1517, 1471, 1322, 1281, 1170, 1098, 946, 782, 742, 729, 703, 663 3, 134.4, 134.2, 132.1, 130.7, 130.3, 129.0, 128.2, 128.1, 128.0, 127.7, 126.9, 126.3, 124.7, 124.2, 124.0, 110.6, 19.6 . IR (neat cm -1 ) 3275, 1636, 1521, 1478, 1327, 1286, 1239, 1089, 951, 822, 741, 718 . Anal. Calcd. for C 20 H 17 NO: C, 83.59; H, 5.96. Found: C, 83.41; H, 6.04 . 33 Synthesized from (E)-(2-bromovinyl)benzene 21 4H), 5H), 7.29 (t, J = 7.6 Hz, 2H), 7.15 (t, J = 7.2 Hz, 1H), 6.74 (d, J = 16.0 Hz, 1H), 6.28 (d, J = 14.8 Hz, 1H ). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 162. 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, 1635 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, , 1606 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, , 1520 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, , 1341 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, , 1234 6, 140.6, 136.5, 134.6, 129.9, 129.0, 128.7, 127.8, 126.2, 125.2, 123.8, 120.9, 112.2. IR (neat cm -1 ) 3373, 3159, 3027, , 1195 .
(E)-
N-((E)-styryl)cinnamamide (3a)
N-((1E,3E)-4-phenylbuta-1,3-dien-1-yl)benzamide (3b)
Synthesized from ((1E)-4-bromobuta-1,3-dien-1-yl)benzene ((3Z) : (3E) = 2.6 : 1.0) 23 (3.76 g, 18.0 mmol, 3. 7.97 (d, J = 7.6 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.53 (t, J = 7.2 Hz, 2H), 7.45 (d, J = 7.6 Hz, 2H), 7.36 (dd, J = 13.6 Hz, 10.4 Hz, 1H), 7.30 (t, J = 7.6 Hz, 2H), 7.18 (t, J = 7.2 Hz, 1H), 7.03 (dd, J = 15.2 Hz, 11.2 Hz, 1H), 6.49 (d, J = 15.6 Hz, 1H), 6.36 (dd, J = 13.2 Hz, 11.6 Hz, 1H ). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 163. 8, 137.6, 133.3, 131.9, 128.6, 128.5, 128.4, 128.1, 128.0, 127.6, 126.7, 125.8, 114.3 . IR (neat cm -1 ) 3328, 3060, 1634, 1510, 1485, 1444, 1340, 1300, 1264, 1150, 1072, 968, 908, 795, 744, 688 . HRMS (ESI) calcd for C 17 H 15 NO [M+H]: 250.1226; found 250.1235 . (E)-3-(3,4-dimethoxyphenyl)-N-((E)-4-methoxystyryl)acrylamide (3c) Synthesized from (E)-1-(2-bromovinyl)-4-methoxybenzene 21 (1.41 g, 6.6 mmol, 1.1 equiv), (E)-3-(3,4-dimethoxyphenyl) 10.29 (d, J = 10.4 Hz, 1H), 7.54 (d, J = 15.6 Hz, 1H), 7.45 (dd, J = 14.8 Hz, 10.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 1.6 Hz, 1H), 7.18 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 8.8 Hz, 2H), 6.59 (d, J = 15.6 Hz, 1H), 6.20 (d, J = 14.8 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H ). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 162. 7, 157.9, 150.5, 148.9, 140.4, 129.1, 127.5, 126.4, 122.1, 121.7, 118.6, 114.2, 111.8, 111.7, 110.2, 55.5, 55.4, 55.0 . IR (neat cm -1 ) 3260, 1640 , 1622 , 1503 , 1440 , 1339 , 1240 , 1190 , 1137 , 1020 H, 6.24. Found: C, 70.48; H, 6.13 .
(E)-N-(dec-1-en-1-yl)benzamide (3d)
Synthesized from (E)-1-iododec-1-ene 22 (2.24 g, 8.4 Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 163. 5, 133.7, 131.5, 128.3, 127.4, 123.6, 113.3, 31.3, 29.61, 29.56, 28.9, 28.7, 28.6, 22.1, 13.9 . IR (neat cm -1 ) 3322, 2922, 2850, 1636, 1518, 1488, 1326, 1294, 1260, 1185, 961, 857, 795, 725, 692, 638 . Anal. Calcd. for C 17 H 25 NO: C, 78.72; H, 9.71. Found: C, 78.91; H, 9.62 .
(E)-N-styrylpivalamide (3e) 37 Synthesized from (E)-(2-bromovinyl)benzene 21 7.45 (dd, J = 14.8 Hz, 10.0 Hz, 1H), 7.31 (d, J = 7.2 Hz, 2H), 7.27 (t, J = 7.2 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 6.33 (d, J = 14.8 Hz, 1H), 1.18 (s, 9H). 13 C NMR (100 MHz, DMSO-d 6 ) δ: 175. 6, 136.9, 128.7, 125.9, 125.0, 124.4, 111.4, 38.3, 27.0 . IR (neat cm -1 ) 3279, 2973, 1632, 1524, 1474, 1398, 1303, 1285, 1235, 1183, 952, 746, 718, 691 .
(E)-N-styrylcyclohexanecarboxamide (3f) 35 Synthesized from (E)-(2-bromovinyl)benzene 21 3, 136.8, 128.6, 125.9, 125.0, 123.9, 111.0, 43.9, 29.0, 25.4, 15.2 . (E)-N-(2-(1-benzoyl-1H-indol-5-yl)vinyl)thiophene-3-carboxamide (3k) Synthesized from 5-(2-bromovinyl)-1H-indol-1-yl)(phenyl)methanone ((Z) : (E) 6, 136.7, 134.1, 134.0, 132.6, 132.0, 131.2, 130.1, 129.0, 128.7, 128.6, 127.1, 127.0, 123.4, 122.1, 117.6, 116.1, 112.8, 108.6 . IR (neat cm -1 ) 3274, 1679, 1633, 1527, 1459, 1367, 1335, 1285, 1190, 1067, 945, 881, 806, 766, 697 (5-20 mol%) , and ligand (0-40 mol%) (if solid). The tube was then evacuated and backfilled with argon (this sequence was repeated a total of three times). Ligand (0-40 mol%) (if liquid) was added into the tube followed by anhydrous acetonitrile (2.0 mL, 0.1 M) via syringe. The sealed tube was then vigorously stirred at room temperature for 24 h. After completion, n-dodecane (20 μL, 0.088 mol) was added into the reaction mixture. The reaction mixture was extracted with ethyl acetate (3 mL) and deionized water (10 mL). Aliquots from the organic fractions were filtered through silica gel for GC analysis to determine the reaction conversion and the GC-yield of 2,5-diphenyloxazole 2a using ndodecane as an internal standard. The aqueous fraction was further washed with ethyl acetate (2 × 3 mL). The combined organic fractions were dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography using ethyl acetate (EtOAc) / hexanes (1:12) as an eluent to afford 2a to determine the isolated yield. (Tables 2 and 3) Unless otherwise noted, an oven-dried 25 mL re-sealable screw-cap test tube equipped with a Teflon-coated magnetic stir bar was charged with enamide (1a-q, 3a-k) (1.0 mmol, 1.0 equiv), copper(II) bromide (CuBr 2 ) (16.8 mg, 0.075 mml, 7.5 mol%), tetrabutylammonium bromide (TBAB) (387 mg, 1.2 mmol, 1.2 equiv), and potassium persulfate (K 2 S 2 O 8 ) (351 mg, 1.3 mmol, 1.3 equiv). The tube was then evacuated and backfilled with argon (this sequence was repeated a total of three times). Ethyl nicotinate (20.5 μL, 0.15 mmol, 15 mol %) was added into the tube followed by anhydrous acetonitrile (10.0 mL, 0.1 M) via syringe. The sealed tube was then vigorously stirred at room temperature for 24 h. After completion, the reaction mixture was extracted with ethyl acetate (10 mL) and deionized water (20 mL). The aqueous fraction was further washed with ethyl acetate (2 × 5 mL). The combined organic fractions were dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography using ethyl acetate (EtOAc) / hexanes as an eluent to afford the oxazole products. Proposed Mechanism for Cu(II)-Catalyzed Oxidative Cyclization of 1a to 2a e GC yield using n-dodecane as an internal standard.
General Procedure for Synthesis of Oxazoles via Cu(II)-Catalyzed Oxidative Cyclization of Enamides
Approaches of Oxazole Synthesis via Cyclization
f Tetrabutylammonium chloride (TBAC) (1.2 equiv) was used.
